OTCMKTS:WINT - Windtree Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.32 -0.08 (-1.82 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$4.40
Today's Range$3.45 - $4.32
52-Week Range$2.05 - $5.35
Volume1,617 shs
Average Volume1,285 shs
Market Capitalization$16.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.03
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:WINT
Previous SymbolNASDAQ:WINT
CUSIP25466840
Phone215-488-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.79 million
Book Value($7.57) per share

Profitability

Net Income$-18,440,000.00
Net Margins-562.41%

Miscellaneous

Employees27
Market Cap$16.87 million
Next Earnings Date5/20/2019 (Estimated)
OptionableNot Optionable

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) announced its quarterly earnings results on Monday, May, 21st. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.20 million for the quarter. View Windtree Therapeutics' Earnings History.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 20th 2019. View Earnings Estimates for Windtree Therapeutics.

Has Windtree Therapeutics been receiving favorable news coverage?

Media stories about WINT stock have been trending positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Windtree Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of Windtree Therapeutics' key competitors?

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Windtree Therapeutics investors own include La Jolla Pharmaceutical (LJPC), XOMA (XOMA), SLS International (SLS), CTI BioPharma (CTIC), Novavax (NVAX), Reshape Lifesciences (RSLS), CorMedix (CRMD), Celldex Therapeutics (CLDX), Microbot Medical (MBOT) and RXi Pharmaceuticals (RXII).

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 54)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 67)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 72)

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $4.32.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $16.87 million and generates $1.79 million in revenue each year. Windtree Therapeutics employs 27 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is http://www.windtreetx.com.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]


MarketBeat Community Rating for Windtree Therapeutics (OTCMKTS WINT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel